Annual Report

Overview

The report describes completion of the ATLAS-IT-04 Phase II study with adoptive cell therapy, including results presented at ASCO 2022. It also reports completion of the preclinical safety program for next-generation molecule LTX-401 as the company prepares for a Phase I trial. In ESG, Lytx conducted stakeholder dialogues and a materiality assessment in Q4 2022, covering environmental, social, and governance priorities.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: Ends 31 December 2022
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services